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ABSTRACT
Objective: Vitamin A supplementation (VAS) is
estimated to reduce all-cause mortality by 24%.
Previous studies indicate that the effect of VAS may
vary with vaccination status. The authors evaluated the
effect of VAS provided in campaigns on child survival
overall and by sex and vaccination status at the time of
supplementation.
Design: Observational cohort study.
Setting and participants: The study was
conducted in the urban study area of the Bandim
Health Project in Guinea-Bissau. The authors
documented participation or non-participation in two
national vitamin A campaigns in December 2007 and
July 2008 for children between 6 and 35 months of
age. Vaccination status was ascertained by inspection
of vaccination cards. All children were followed
prospectively.
Outcome measures: Mortality rates for
supplemented and non-supplemented children were
compared in Cox models providing mortality rate
ratios (MRRs).
Results: The authors obtained information from
93% of 5567 children in 2007 and 90% of 5799
children in 2008. The VAS coverage was 58% in 2007
and 68% in 2008. Mortality in the supplemented group
was 1.5% (44 deaths/2873 person-years) and
1.6% (20 deaths/1260 person-years) in the
non-supplemented group (adjusted MRR¼0.78
(0.46; 1.34)). The effect was similar in boys and girls.
Vaccination cards were seen for 86% in 2007 and 84%
in 2008. The effect of VAS in children who had measles
vaccine as their last vaccine (2814 children, adjusted
MRR¼0.34 (0.14; 0.85)) differed from the effect in
children who had diphtheriaetetanusepertussis
vaccine as their last vaccine (3680 children,
adjusted MRR¼1.29 (0.52; 3.22), p¼0.04 for
interaction).
Conclusion: The effect of VAS differed by most recent
vaccination, being beneﬁcial after measles vaccine but
not after diphtheriaetetanusepertussis vaccine.
INTRODUCTION
Vitamin A supplementation (VAS) is esti-
mated to reduce all-cause mortality by 24%
when provided to children aged 6e59
months at four to six monthly intervals.
1
However, according to a preliminary report
2
of a recent cluster randomised trial involving
>1 million Indian children, VAS compared
with no VAS was associated with no survival
beneﬁt. We have hypothesised that the
effect of VAS varies with vaccination status
because VAS ampliﬁes the non-speciﬁc
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ARTICLE SUMMARY
Article focus
- Vitamin A supplementation (VAS) is estimated to
reduce all-cause mortality by 24%.
- The effect of VAS may vary with vaccination
status, being beneﬁcial with or after measles
vaccine (MV) but not after diphtheriae
tetanusepertussis (DTP) vaccine.
Key messages
- The effect of VAS is heterogeneous.
- The effect of VAS varied with vaccination status:
supplemented children had lower mortality than
non-supplemented children when MV was the
most recent vaccine but not when DTP was the
most recent vaccine.
- The effect of VAS tended to differ by season of
supplementation.
Strengths and limitations of this study
- Information was collected on the individual level,
and the children were followed prospectively.
- Due to the observational nature of the study, the
comparison of supplemented and non-supple-
mented children should be interpreted with
caution.
- However, a selection bias is unlikely to have
worked in different directions for children who
had DTP and MV as the most recent vaccine.
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3 Hence, VAS is
beneﬁcial in the time window when BCG (recom-
mended at birth) and measles vaccine (MV, recom-
mended at 9 months of age) are the most recent
vaccines but not while diphtheriaetetanusepertussis
vaccine (DTP, recommended at 6, 10 and 14 weeks of
age) is the most recent vaccine.
3 The hypothesis provides
an explanation of the lack of a beneﬁcial effect of VAS in
children aged 1e5 months,
45the age group in which
DTP is the predominant vaccine. The hypothesis also
offers an explanation of why the large mortality reduc-
tion reported by the meta-analysis of the trials between
1986 and 1993
1 may no longer be reproducible; these
trials were conducted before the Expanded Programme
on Immunisations reached high coverage.
6 We recently
reanalysed data from the 1989 to 1991 VAS trial in
Ghana, which had reported an overall mortality reduc-
tion of 19% (2%; 32%).
7 The reanalysis revealed that the
survival advantage was limited to children with no health
card (a proxy for being unvaccinated). Among vacci-
nated children, there was a harmful effect of VAS among
girls likely to receive DTP during follow-up.
8
WHO recommends vitamin A for all children aged
6e59 months distributed in campaigns or at vaccination
contacts in areas where vitamin A deﬁciency is a public
health problem.
9 10 In Guinea-Bissau, VAS is distributed
in biannual campaigns, often linked to other interven-
tions such as distribution of mebendazole, oral polio
vaccine (OPV) or other vaccines.
11 Two different strate-
gies have been employed in the urban area: ﬁxed post
campaigns where the mother brings her child to the
campaign team and door-to-door campaigns where all
houses are visited by the campaign team. The ﬁxed post
campaigns require less staff but have lower coverage. In
December 2007 and June/July 2008, ﬁxed post
campaigns distributing vitamin A and mebendazole were
conducted. We registered all children receiving VAS and
mebendazole during these campaigns and assessed
survival prospectively to compare survival in supple-
mented and non-supplemented children overall and by
sex and vaccination status.
SUBJECTS AND METHODS
Setting
The Bandim Health Project (BHP) operates a health
and demographic surveillance system (HDSS) covering
a population of 102000 people in six suburban districts
of Bissau, the capital of Guinea-Bissau, West Africa. All
households are visited monthly to register new births,
pregnancies and deaths. Children below the age of 3 are
followed through three monthly visits to ascertain vital
status and vaccination status. At the ﬁrst visit, after birth
information on socioeconomic status is collected. The
indicators include maternal characteristics (education
and ethnicity) and household characteristics (type of
rooﬁng, availability of bathroom and electricity). All
children aged 6e35 months living in the urban study
area on the ﬁrst day of the VAS campaigns in 2007 and
2008 were eligible for the present study. Since children
below 3 years of age are followed intensively through the
HDSS, these children have been the focus for the
present study.
WHO classiﬁes Guinea-Bissau as having a public health
problem of VAS.
12 We have previously found that 16% of
4-month-old children were vitamin A deﬁcient (retinol-
binding protein concentration equivalent to plasma
retinol <0.70 mmol/l).
13 During 2007e2008, we assessed
vitamin A status in 181 children aged 6e17 months
presenting for vaccinations and found that 70% of the
children had a retinol-binding protein concentration
equivalent to plasma retinol <0.70 mM (unpublished
data).
Campaign information
National VAS campaigns were conducted by the Ministry
of Health from 14 to 18 December 2007 and 30 June to
4 July 2008. Children aged 6e11 months received
100000 IU vitamin A, children aged 12e35 months
received 200000 IU vitamin A and 250 mg mebendazole
and children aged 36e59 months received 200000 IU
vitamin A and 500 mg mebendazole. Trained BHP ﬁeld
assistants were present at all posts. The ﬁeld assistants
brought a list of all children registered in the area and
noted on this list whether a child had received VAS and
mebendazole at the post. The lists contained informa-
tion on vaccines registered prior to the campaign. If the
vaccination card was seen, the assistant noted this on the
list, veriﬁed the already registered vaccines and updated
the information if new vaccines had been received.
During the weeks after the campaigns, all children
who had not been seen during the campaigns were
visited. The caretaker was asked whether the child had
received VAS elsewhere. The vaccination card was seen
and information on vaccines veriﬁed and updated. If the
child and caretaker were not present, the household was
visited up to three times, and if no one could provide
information, the campaign status was classiﬁed as
unknown.
During the 2007 campaign, we discovered that the
vitamin A capsules given in two of the six districts had
been produced in November 2004 and had passed the
expiry date 1 month before. The capsules were imme-
diately replaced by a new batch. We sent two of the
expired 200000 IU capsules to ‘as Vitas Oslo Innovation
Center’ (Oslo, Norway) to have their vitamin A content
measured. The vitamin A contents were slightly lower
than expected: 167569 IU and 154863IU. Capsules
used in the 2008 campaign were all from a new stock.
Vaccine information
The vaccination schedule in Guinea-Bissau when this
study was conducted was BCG and OPV at birth, three
doses of DTP vaccines at 6, 10 and 14 weeks of age and
MV at 9 months of age. A booster DTP vaccine at
18 months of age was given in the routine vaccination
programme until March 2007 after which it was only
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2008, the DTP vaccine at 6, 10 and 14 weeks was replaced
by the pentavalent (DTPeHiBeHBV) vaccine and
a yellow fever vaccine was added to be given with MV at
9 months of age.
During the study period, three trials of alternative
vaccination strategies took place in the BHP area. First,
between October 2005 and October 2009, trial A
enrolled children aged 18 months in a randomised trial
of booster DTP. Children who had completed their
primary immunisation schedule of three doses of DTP
and an MV were randomised to receive booster DTP
+OPV or OPV only. Second, between August 2003 and
April 2007, trial B enrolled children aged 4.5 months in
a randomised trial of early MV. Children were rando-
mised to an extra dose of MV at 4.5 months or no
vaccine; a subgroup of the controls received an extra MV
at 18 months of age.
14 Third, between October 2005 and
April 2008, trial C enrolled children aged at least
9 months who were delayed in relation to the vaccina-
tion schedule and presented at the health centres to
receive MV and the third DTP vaccine. They were
randomised to receive both vaccines and booster DTP at
18 months of age versus MV only and no booster DTP
15
(supplementary ﬁgure). Furthermore, in May 2006,
a measles vaccination campaign was conducted in which
children aged 6 months to 14 years were given an MV;
thus, the oldest children in the present study often had
MV received in this campaign as their most recent
vaccine.
For the present study, vaccine status was ascertained
during the campaigns. Furthermore, as part of the BHP
routines, vaccines are registered daily at the three health
centres in the study area and through the tri-monthly
home visits and as a part of the trials described above. We
linked the campaign information with information from
the above sources, using only information collected
prior to the campaign. In case of discrepancy, informa-
tion from the trials was considered superior. If no trial
information was available and if two of the other sources
agreed, this information was accepted. Vaccination
information obtained during the campaign was updated
for 12% (1088/8812) of the children: 9% based on data
collected at the health centres, 1% based on routine
surveillance data and 2% based on trial data. Except for
children included in trial A, OPV is almost always given
with BCG or DTP. In line with previous studies,
11 16
children who received OPV along with another vaccine
were classiﬁed according to the co-administered vaccine,
that is, children who received DTP alone (161 children)
and DTP+OPV (3519 children) were classiﬁed as DTP
and children who received MV+OPV (205 children) and
MV alone (2609) were classiﬁed as MV.
Follow-up
All children below 3 years of age were followed by the
HDSS. For children who died, a locally adapted version
of the INDEPTH verbal autopsy
17 was conducted. Cause
of death was determined by a local paediatrician.
Statistical analyses
Children entered the analysis on the day we knew their
VAS campaign status (supplemented, non-supplemented
or no information). Thus, a child who was registered to
have participated in the campaign during the days of the
campaign contributed time at risk from the day of
supplementation. A child who had campaign status
registered after the campaign contributed time from the
day the information was obtained. Follow-up of children
was censored when a subsequent campaign was initiated
(30 June 2008 for the 2007 campaign and 9 January 2009
for the 2008 campaign), 3 years of age, migration or
reception of VAS in a trial, whichever came ﬁrst. Some
children were enrolled in a randomised trial of VAS at
vaccination contacts after 6 months of age (Trial regis-
tration: clinicaltrials.gov, NCT00514891). These children
were censored from follow-up on the date of receiving
VAS in the trial (ﬁgure 1).
We examined whether the background factors were
evenly distributed between children in the VAS, no VAS
and no information group, as well as between the two
main groups (VAS and no VAS) using c
2 tests for cate-
gorical variables and rank-sum test for age at the time of
the campaign.
Survival was examined in Cox proportional hazards
models with age as underlying time; thus, age was
inherently controlled for in all models. The proportional
hazards assumption was tested using Schoenfeld resid-
uals. Crude and adjusted estimates are presented. The
2007 campaign took place in the dry season and the
2008 campaign in the rainy season. A priori we had
decided to adjust all estimates for sex and campaign
since sex and season of supplementation have been
shown to be important determinants of the effect of VAS
in our previous studies.
8 18 19 We furthermore adjusted
the comparison of supplemented and non-supple-
mented children for the background factors which were
associated with participation in the VAS campaigns. In
all analyses, we investigated whether the survival of
supplemented and non-supplemented children varied
by sex and campaign (season). We furthermore investi-
gated interactions with vaccination status. Interaction
between VAS and potential effect modiﬁer was evaluated
by Wald statistics. Among children who had OPV as the
most recent vaccine prior to the campaign, no deaths
occurred among children who did not receive VAS.
Therefore, the potential interaction between VAS and
OPV was tested by ManteleHaenszel stratiﬁcation.
Finally, previous studies have indicated that the effect of
VAS in girls depends on whether or not they have
received VAS on a previous occasion.
20 21 We therefore
investigated whether survival after the 2008 campaign
varied with reception of VAS in the 2007 campaign.
RESULTS
In the 2007 campaign, we followed 5567 (92%) of the
6026 children aged 6e35 months registered in the study
area. Reasons for losses to follow-up are given in ﬁgure 1.
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campaign status since the family was travelling at all
visits. Among the remaining 5200 children, 3009 (58%)
had received VAS and 2191 (42%) had not. In the 2008
campaign, we followed 5799 (93%) of 6210 children. For
10% (596/5799), we were unable to obtain information
on campaign status. Among the remaining 5203 chil-
dren, 3520 (68%) had received VAS and 1683 (32%) had
not (ﬁgure 1). Median length of follow-up and IQR was
6.2 (4.4e6.4) months for supplemented, 4.2 (3.2e5.1)
months for non-supplemented and 2.9 (1.8e3.4)
months for children for whom we did not obtain
information.
The distribution of background factors is shown in
table 1. Children for whom we had no information on
campaign status had lower socioeconomic status, were
more likely to be from the Muslim ethnic groups (Fula
and Mandinga) and were younger. These children also
tended to have higher mortality, crude mortality rate
ratio (MRR)¼2.17 (0.96; 4.94) (table 2). In contrast,
there were only few differences in background factors
between supplemented and non-supplemented chil-
dren. Non-supplemented children were more likely to
have mothers with no formal education (p<0.001), to
belong to the Muslim ethnic groups (p<0.001) and were
less likely to have their vaccination card inspected
(p<0.001). Furthermore, more supplemented children
were enrolled in trials and as a result more supple-
mented children had received OPV as the most recent
vaccine in 2007 (p¼0.05). In 2008, the distribution of
Figure 1 Flowchart of children
eligible for campaign participation.
BHP, Bandim Health Project;
RCT, randomised controlled trial;
VAS, vitamin A supplementation.
Elligible for campaign: living in 
the urban BHP area 14 
December 2007 and aged 6–
35 months: (n=6026)
Available for analysis (n=5567)
Campaign 
2007  
status:
Received VAS (n=3009)
2739 VAS registered 
during the campaign
270 VAS registered after 
campaign
Received no 
VAS 
(n=2191)
Excluded: unknown campaign 
status and censored (n=459): 
3 not visited
158 moved before visit
9 died prior to visit
273 completed 3 years prior to visit 
11 received VAS in RCT between 
campaign and visit
5 VAS shortly before the campaign
Follow-up 
status:
Dead              (n=6) 
Moved        (n=176)
3 years       (n=562)
VAS in RCT (n=69)
Newly added 
(n=2027)
1561 children born 
after 14 June 2007
235 newly registered
231 returned to 
area/excluded in 
previous campaign
Unknown campaign status 
but followed up (n=367)
297 child and caretaker 
travelling at all visits 
70 informant did not know if 
the child had received VAS
Dead              (n=8) 
Moved        (n=122)
3 years      (n=350)
VAS in RCT (n=34)
Dead           (n=1) 
Moved       (n=36)
3 years      (n=20)
VAS in RCT (n=0)
In study 30 June 
2008  (n=2196)
In study 30 June 
2008  (n=310)
In study 30 June 
2008  (n=1677)
Elligible for campaign: living in 
the urban BHP area 30 June 
2008 and aged 6–35 months: 
(n=6210)
Available for analysis (n=5799)
Received VAS (n=3520)
3167 VAS registered 
during the campaign
353 VAS registered after 
campaign
Received no 
VAS 
(n=1683)
Excluded: unknown campaign 
status and censored (n=411): 
6 not visited
197 moved before visit
17 died prior to visit
154 completed 3 years prior to visit
37 received VAS in RCT between 
campaign and visit
Dead              (n=38) 
Moved          (n=183)
3 years        (n=602)
VAS in RCT (n=133)
Unknown campaign status 
but followed up (n=596)
521 child and caretaker 
travelling at all visits 
75 informant did not know if 
the child had received VAS
Dead            (n=12) 
Moved          (n=71)
3 years       (n=261)
VAS in RCT (n=58)
Dead            (n=7)
Moved        (n=59)
3 years       (n=70)
VAS in RCT (n=8)
Followed to 9 
January 2009 
(n=2564)
Followed to 9 
January 2009
(n=452)
Followed to 9 
January 2009 
(n=1281)
Campaign 
2008 
status:
Follow-up 
status:
Remained in study (n=4183)
Campaign 2008
Campaign 2007
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Vitamin A in campaigns and child survivaldifferent vaccines did not differ between supplemented
and non-supplemented children (p¼0.23) (table 1).
Effect of VAS
There was no signiﬁcant difference in mortality between
supplemented and non-supplemented children, the
crude MRR being 0.93 (0.55; 1.58). When the estimate
was adjusted for sex, campaign, maternal education,
ethnicity and inspected vaccination card, the difference
in mortality between supplemented and non-supple-
mented children was 0.78 (0.46; 1.34) (table 2). The
effect did not differ signiﬁcantly for children aged
6e11 months who received 100000 IU vitamin A
(adjusted MRR¼1.14 (0.41; 3.19)) and children above
12 months who received 200000 IU vitamin A and
250 mg mebendazole (adjusted MRR¼0.69 (0.36; 1.29))
(p¼0.41, test of interaction) (table 2). The effect did not
differ for boys and girls (p¼0.72).
Mortality was much higher in the rainy season after the
2008 campaign (57 deaths/2208 person-years) than in
the dry season after the 2007 campaign (15 deaths/2154
person-years); the adjusted MRR was 3.79 (2.13; 6.74)
comparing 2008 versus 2007. The difference between
supplemented and non-supplemented tended to differ
between the two campaigns; the adjusted MRR was 0.38
(0.13; 1.10) after the 2007 campaign and 1.02 (0.53;
1.96) after the 2008 campaign (p¼0.12, test of interac-
tion). This difference may have been strongest for girls;
the adjusted MRR was 0.16 (0.02; 1.59) after the 2007
campaign and 1.32 (0.44; 3.94) after the 2008 campaign
(p¼0.11, test of interaction), whereas there was no
evidence of a difference in boys (p¼0.50) (table 2).
Further adjusting for last vaccine at the time of the
campaign did not change the conclusions.
The difference between supplemented and non-
supplemented children varied with maternal education.
Supplementation was associated with lower mortality in
children of educated mothers (adjusted MRR¼0.41
(0.21; 0.80)) but not in children of mothers with no
schooling (adjusted MRR¼1.78 (0.60; 5.31)) (p¼0.02,
test of interaction). The effect did not vary with the
other socioeconomic indicators presented in table 1
(data not shown).
Effect of VAS by vaccination status
Vaccination cards were seen for 86% of the children in
2007 and 84% in 2008, with more cards seen for
supplemented compared with non-supplemented chil-
dren (2007: 90% vs 81%, p<0.001; 2008: 88% vs 75%,
p<0.001, table 1); 9% (6/64) of the deaths in the study
were excluded due to no information on vaccination
status.
The difference in mortality between supplemented
and non-supplemented children varied with vaccination
status. In the 2814 children who had received MV as
the most recent vaccine prior to the campaign, the
adjusted MRR was 0.34 (0.14; 0.85). In the 3680 children
who had received DTP as the most recent vaccine, the
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Vitamin A in campaigns and child survivaladjusted MRR was 1.29 (0.52; 3.22) (p¼0.04 for different
effect in MV and DTP recipients). The pattern was
similar in boys and girls (table 3). The small group
of non-supplemented children with OPV as the most
recent vaccine had lower mortality than all other groups
(table 3).
Effect of supplementation in the 2007 campaign on survival
after the 2008 campaign
Supplementation in the 2007 campaign was associated
with improved survival after the 2008 campaign. Among
3520 children supplemented in 2008, 69% (2441) had
been eligible for supplementation in 2007; 1435 (59%)
had received VAS, 917 (38%) had not and 89 (4%) had
no information on participation. After the 2008
campaign, children supplemented in both campaigns
had lower mortality (8 deaths/623 person-years) than
children who had not received VAS in 2007 but received
VAS in 2008 (15 deaths/394 person-years), the adjusted
MRR being 0.34 (0.14; 0.80). This beneﬁcial effect of
prior VAS was more pronounced for girls (MRR¼0.14
(0.03; 0.68)) than for boys (MRR¼0.59 (0.20; 1.77)) (test
of interaction between sex and VAS, p¼0.14).
Cause of death
We aimed to examine the effect of VAS on all-cause
mortality. However, from May 2008 to January 2009
a cholera epidemic occurred.
22 This epidemic could
potentially explain the higher mortality after the 2008
campaign. Verbal autopsies were conducted for 66 of the
72 deaths, for the remaining six the family had moved
prior to the interview. One death which occurred after
receiving VAS in 2008 was classiﬁed as due to cholera.
Further 10 deaths (15%) were due to diarrhoeal disease,
one after the 2007 campaign (no VAS) and nine after the
2008 campaign (eight VAS and one no VAS). The peak
of the epidemic occurred in September 2008
22; ﬁve
diarrhoeal deaths in 2008 occurred in August and
September (all VAS) and four deaths (three VAS and
one no VAS) occurred in the late epidemic in November
and December where few cholera cases were detected.
Campaign participation had no signiﬁcant effect on the
risk of death due to diarrhoea, the MRR being 1.87
(0.40; 8.71). The other causes of death were prolonged
disease with failure to thrive and anaemia, 18 (27%, 14
VAS, three no VAS and one no information); respiratory
infection, 17 (26%, nine VAS, six no VAS and two no
information); malaria, 14 (21%, ﬁve VAS, seven no VAS
and two no information); fever of unknown origin, three
(5%, two VAS and one no VAS); cerebral palsy, two (3%,
one VAS and one no VAS) and accident, one (2%, VAS).
There were signiﬁcantly more malaria deaths among the
non-supplemented and the children with no informa-
tion, the MRRs being 3.26 (1.03; 10.3) and 5.43 (1.05;
28.2), respectively, presumably reﬂecting that they were
less likely to seek early treatment or to be absent in the
rural areas where the incidence of severe and untreated
malaria would be higher.
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Vitamin A in campaigns and child survivalDISCUSSION
Based on the marked mortality reductions seen in trial in
the 1980s and 1990s, VAS has become a high-priority
intervention, expected to reduce overall child mortality.
However, according to the preliminary report, a recent
trial VAS in 1 million Indian children has not shown the
same beneﬁcial effect.
2
In our study, children receiving VAS in a campaign had
7% ( 58%; 45%) lower mortality compared with non-
supplemented children in the crude analysis and 22%
( 34%; 54%) lower mortality in the adjusted analysis.
However, this is unlikely to represent the true effect of
VAS since there are many reasons that non-supple-
mented children may have had higher mortality, for
example, selection bias, travelling to the rural areas, less
access to care and a higher risk of dying of malaria. More
important, our observational study identiﬁed differential
effects of VAS by season and vaccination status; for
example, supplemented children did not have lower
mortality than non-supplemented children in the rainy
season and among children who had DTP as the most
recent vaccination.
Strengths and weaknesses
The strengths of our study include that information was
collected on the individual level and that the children
were followed prospectively. By only allowing the chil-
dren to contribute observation time in the VAS or no
VAS group from the day the information was obtained,
we avoided introducing survival bias in the analysis
(ie, obtaining positive information only from surviving
children).
23
Vitamin A content was assessed in the expired capsules
which some campaign recipients received in 2007.
Though the content was lower than the original
200000 IU, the content was still high. Hence, we believe
that all supplemented children received a relevant dose
of vitamin A.
Mortality was higher in children for whom we do not
have information on the campaign participation and
also a substantial number of children died prior to us
getting the information on their participation in the VAS
campaign. The main reason for not getting any infor-
mation was that the family had travelled to the rural
areas, where mortality is higher.
24 According to national
data, VAS coverage was considerably higher outside
the capital and hence outside the urban study area
(personal communication, Sidu Biai, WHO, Bissau).
Hence, the children for whom we did not obtain infor-
mation may have been supplemented in the rural areas
and if anything more of the deaths among travelling
children may have occurred in supplemented than
non-supplemented children.
Consistency with other studies
Apart from our previous studies from Bissau,
11 19 24 there
has been no evaluation of the impact of VAS campaigns
on mortality based on individual level data. We have
previously shown that the effect of VAS was more
beneﬁcial when provided with MV than with DTP
vaccine.
11 We have also gathered evidence that the effect
of VAS versus placebo was more beneﬁcial in girls with
MV than in girls with DTP as their most recent vaccine.
8
In the present study, we compared campaign partici-
pants with non-participants rather than VAS with
placebo recipients, which may have introduced selection
biases in the comparison of VAS recipients and non-
recipients. However, the varying effect by vaccination
status is unlikely to be explained by simple selection bias.
We had expected that a negative effect of VAS with DTP
would be most pronounced for girls.
82 52 6This was not
the case. However, recent studies have indicated that
mortality after VAS is lowered in girls who have received
VAS on a previous occasion,
20 21 and this was also the
case in the present study. Thus, repeated dosing may
have alleviated the negative effects of VAS with DTP in
girls.
Mortality is usually 15% higher in the rainy (May to
November) than in the dry season,
27 and though this
may explain some of the differences in mortality after
the 2007 and 2008 campaigns, it is unlikely to explain
the threefold higher mortality. The difference may partly
be due to a more beneﬁcial effect of VAS in the dry than
in the rainy season (table 2). We have previously found
strong differences in the effect of neonatal VAS by
season. In a randomised trial, neonatal VAS beneﬁted
infant survival among normal birth weight neonates in
the dry season but was associated with increased
mortality in the rainy season.
18 However, we found no
seasonal differences in the effect of neonatal VAS to low
birth weight infants
26 and no strong seasonal pattern was
seen in Ghana where an analysis by season has been
reported.
28 Though numbers were small and the differ-
ence was not statistically signiﬁcant, VAS appeared to be
associated with an increased risk of dying of diarrhoea
during the cholera epidemic in 2008. This contrasts with
a recent meta-analysis that estimates 28% (9%; 43%)
reduction in diarrhoea-related mortality.
1
The effect of VAS on mortality has most often been
ascribed to prevention and treatment of vitamin A deﬁ-
ciency.
29 We have previously found poorer vitamin A
status in children of non-educated mothers.
13 In the
current study, we found no evidence of a beneﬁcial
effect limited to lower socioeconomic groups, which
presumably are the most vitamin A deﬁcient.
Interpretation
The present study as well as previous observations
support that the effect of VAS differs depending on
vaccination status being beneﬁcial when provided after
MV
3 8 but not after DTP. This is unlikely to be explained
by selection bias since bias is unlikely to work in different
direction for children who had MV or DTP as their most
recent vaccine. It is also unlikely to be explained by
differences in vitamin A deﬁciency.
We do not know what may have caused the observed
tendency for a differential effect of VAS on mortality
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Vitamin A in campaigns and child survivalbetween the two campaigns. Previous studies have
demonstrated seasonal variance in pathogen prevalences
with distinct season-related epidemics of rotavirus,
30
cryptosporidium,
31 respiratory syncytial virus
32 as well as
a malaria.
33 The effect of VAS has been show to differ
depending on the pathogen,
34 and varying pathogen
prevalences may therefore contribute to the seasonal
differences. Based on the verbal autopsy data, VAS may
have been associated with a higher risk of dying from
cholera/diarrhoea during the cholera epidemic in 2008.
An alternative explanation is the generally increased
prevalence of infectious diseases in the rainy season,
which may lead to impaired uptake and increased
excretion of vitamin A.
35 This could explain the lack of
effect during the rainy season but would not explain the
vaccine differential effect. Regardless of the mechanism,
the potential differential seasonal effects of VAS deserve
further investigation.
Implications and conclusions
Our present study highlights the importance of
continuing to evaluate the effect of presumed beneﬁcial
interventions. The circumstances under which the
intervention is being implemented may differ from the
circumstances under which it was originally tested.
The present study as well as several previous studies
suggest that the effect of VAS is beneﬁcial when admin-
istered with or after MV
3 81 13 6but not when adminis-
tered with or after DTP/pentavalent.
481 13 7 e41 Hence,
in a situation where children with DTP as the most
recent vaccination predominate, the overall effect of
VAS campaigns could be negative. From this perspective,
it may be no coincidence that the recent huge trial of 1
million children in India, where a booster dose of DTP is
recommended at 18 months of age,
42 showed no
beneﬁcial effect of biannual VAS.
2
Our research questions the current focus on
up-scaling VAS and integrating interventions to achieve
higher coverage.
43 We ﬁrst need to understand under
which conditions VAS does not have a beneﬁcial effect.
In a recent meta-analysis,
14 4it is argued that no further
placebo-controlled trials are needed. The meta-analysis
is essentially based on trials from the late 1980s and early
1990s and to declare that no further trials are needed
presupposes that it can be shown that the effect has not
changed over time. The only recent trials are the mega-
trial from India showing no effect
2 and a placebo-
controlled trial of VAS administered with vaccines in
Guinea-Bissau also showing no overall but sex-differen-
tial effects (unpublished data). Hence, the effect of VAS
may have changed, and placebo-controlled trials may be
needed to clarify whether season matters and with which
vaccines VAS should be given.
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